171 related articles for article (PubMed ID: 35846215)
1. Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma.
Martin T; Krishnan A; Yong K; Weisel K; Mehra M; Nair S; Qi K; Londhe A; Diels J; Crivera C; Jackson CC; Olyslager Y; Vogel M; Schecter JM; Banerjee A; Valluri S; Usmani SZ; Berdeja JG; Jagannath S
EJHaem; 2022 Feb; 3(1):97-108. PubMed ID: 35846215
[TBL] [Abstract][Full Text] [Related]
2. Meta-analysis of ciltacabtagene autoleucel versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myeloma.
Costa LJ; Hari P; Berdeja JG; De Stefano V; Gay F; Hooper B; Bartlett M; Haltner A; Rosta E; Kumar S; Martin T; Mateos MV; Moreau P; Usmani SZ; Olyslager Y; Schecter JM; Roccia T; Garrett A; Lee S; Nesheiwat T; Pacaud L; Zhou C; Samjoo IA; Lin Y; Diels J; Valluri S; Weisel K
Curr Med Res Opin; 2022 Oct; 38(10):1759-1767. PubMed ID: 35815818
[No Abstract] [Full Text] [Related]
3. Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.
Martin T; Usmani SZ; Schecter JM; Vogel M; Jackson CC; Deraedt W; Tian H; Yeh TM; Banerjee A; Pacaud L; Garrett A; Haltner A; Cameron C; Van Sanden S; Diels J; Valluri S; Samjoo IA
Curr Med Res Opin; 2021 Oct; 37(10):1779-1788. PubMed ID: 34256668
[TBL] [Abstract][Full Text] [Related]
4. Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma.
Weisel K; Martin T; Krishnan A; Jagannath S; Londhe A; Nair S; Diels J; Vogel M; Schecter JM; Banerjee A; Berdeja JG; Nesheiwat T; Garrett A; Qi K; Valluri S; Usmani SZ; Yong K
Clin Drug Investig; 2022 Jan; 42(1):29-41. PubMed ID: 34822128
[TBL] [Abstract][Full Text] [Related]
5. Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.
Martin T; Usmani SZ; Schecter JM; Roccia T; Jackson CC; Deraedt W; Yeh TM; Banerjee A; Pacaud L; Garrett A; Bartlett M; Haltner A; Van Sanden S; Diels J; Valluri S; Samjoo IA
Curr Med Res Opin; 2023 Jan; 39(1):81-89. PubMed ID: 36271807
[TBL] [Abstract][Full Text] [Related]
6. Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma.
Weisel K; Krishnan A; Schecter JM; Vogel M; Jackson CC; Deraedt W; Yeh TM; Banerjee A; Yalniz F; Nesheiwat T; Van Sanden S; Diels J; Valluri S; Usmani SZ; Berdeja JG; Jagannath S; Martin T
Clin Lymphoma Myeloma Leuk; 2022 Sep; 22(9):690-701. PubMed ID: 35764490
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma.
Costa LJ; Lin Y; Cornell RF; Martin T; Chhabra S; Usmani SZ; Jagannath S; Callander NS; Berdeja JG; Kang Y; Vij R; Godby KN; Malek E; Neppalli A; Liedtke M; Fiala M; Tian H; Valluri S; Marino J; Jackson CC; Banerjee A; Kansagra A; Schecter JM; Kumar S; Hari P
Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):326-335. PubMed ID: 34840088
[TBL] [Abstract][Full Text] [Related]
8. Adjusted Comparison of Outcomes between Patients from CARTITUDE-1 versus Multiple Myeloma Patients with Prior Exposure to PI, Imid and Anti-CD-38 from a German Registry.
Merz M; Goldschmidt H; Hari P; Agha M; Diels J; Ghilotti F; Perualila NJ; Cabrieto J; Haefliger B; Sliwka H; Schecter JM; Jackson CC; Olyslager Y; Akram M; Nesheiwat T; Kellermann L; Jagannath S
Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885106
[TBL] [Abstract][Full Text] [Related]
9. Adjusted comparison of outcomes between patients from CARTITUDE-1
Mateos MV; Weisel K; Martin T; Berdeja JG; Jakubowiak A; Stewart AK; Jagannath S; Lin Y; Diels J; Ghilotti F; Thilakarathne P; Perualila NJ; Cabrieto J; Haefliger B; Erler-Yates N; Hague C; Jackson CC; Schecter JM; Strulev V; Nesheiwat T; Pacaud L; Einsele H; Moreau P
Haematologica; 2023 Aug; 108(8):2192-2204. PubMed ID: 36546453
[TBL] [Abstract][Full Text] [Related]
10. Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up.
Martin T; Usmani SZ; Berdeja JG; Agha M; Cohen AD; Hari P; Avigan D; Deol A; Htut M; Lesokhin A; Munshi NC; O'Donnell E; Stewart AK; Schecter JM; Goldberg JD; Jackson CC; Yeh TM; Banerjee A; Allred A; Zudaire E; Deraedt W; Olyslager Y; Zhou C; Pacaud L; Madduri D; Jakubowiak A; Lin Y; Jagannath S
J Clin Oncol; 2023 Feb; 41(6):1265-1274. PubMed ID: 35658469
[TBL] [Abstract][Full Text] [Related]
11. Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study.
Martin T; Lin Y; Agha M; Cohen AD; Htut M; Stewart AK; Hari P; Berdeja JG; Usmani SZ; Yeh TM; Olyslager Y; Goldberg JD; Schecter JM; Madduri D; Jackson CC; Deraedt W; Gries KS; Fastenau JM; Trudeau JJ; Akram M; Pacaud L; Jakubowiak A; Jagannath S
Lancet Haematol; 2022 Dec; 9(12):e897-e905. PubMed ID: 36215989
[TBL] [Abstract][Full Text] [Related]
12. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Berdeja JG; Madduri D; Usmani SZ; Jakubowiak A; Agha M; Cohen AD; Stewart AK; Hari P; Htut M; Lesokhin A; Deol A; Munshi NC; O'Donnell E; Avigan D; Singh I; Zudaire E; Yeh TM; Allred AJ; Olyslager Y; Banerjee A; Jackson CC; Goldberg JD; Schecter JM; Deraedt W; Zhuang SH; Infante J; Geng D; Wu X; Carrasco-Alfonso MJ; Akram M; Hossain F; Rizvi S; Fan F; Lin Y; Martin T; Jagannath S
Lancet; 2021 Jul; 398(10297):314-324. PubMed ID: 34175021
[TBL] [Abstract][Full Text] [Related]
13. Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 Study.
Cohen AD; Hari P; Htut M; Berdeja JG; Usmani SZ; Madduri D; Olyslager Y; Goldberg JD; Schecter JM; Jackson CC; Gries KS; Fastenau JM; Valluri S; Deraedt W; Akram M; Crawford R; Morrison R; Doward L; Morgan K; Seldam ST; Jakubowiak A; Jagannath S
Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):68-77. PubMed ID: 36357295
[TBL] [Abstract][Full Text] [Related]
14. Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 (phase 2) Japanese cohort.
Ri M; Suzuki K; Ishida T; Kuroda J; Tsukamoto T; Teshima T; Goto H; Jackson CC; Sun H; Pacaud L; Fujikawa E; Yeh TM; Hatayama T; Aida K; Sunagawa Y; Iida S
Cancer Sci; 2022 Dec; 113(12):4267-4276. PubMed ID: 36052883
[TBL] [Abstract][Full Text] [Related]
15. Recent Advances in the Use of Chimeric Antigen Receptor-Expressing T-Cell Therapies for Treatment of Multiple Myeloma.
Martin T; Jackson CC; Pacaud L; Madduri D; Jagannath S
Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):22-27. PubMed ID: 36411210
[TBL] [Abstract][Full Text] [Related]
16. Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study.
Htut M; Dhakal B; Cohen AD; Martin T; Berdeja JG; Usmani SZ; Agha M; Jackson CC; Madduri D; Deraedt W; Zudaire E; Yeh TM; Xu X; Pacaud L; Akram M; Jagannath S
Clin Lymphoma Myeloma Leuk; 2023 Dec; 23(12):882-888. PubMed ID: 37716872
[TBL] [Abstract][Full Text] [Related]
17. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
San-Miguel J; Dhakal B; Yong K; Spencer A; Anguille S; Mateos MV; Fernández de Larrea C; Martínez-López J; Moreau P; Touzeau C; Leleu X; Avivi I; Cavo M; Ishida T; Kim SJ; Roeloffzen W; van de Donk NWCJ; Dytfeld D; Sidana S; Costa LJ; Oriol A; Popat R; Khan AM; Cohen YC; Ho PJ; Griffin J; Lendvai N; Lonardi C; Slaughter A; Schecter JM; Jackson CC; Connors K; Li K; Zudaire E; Chen D; Gilbert J; Yeh TM; Nagle S; Florendo E; Pacaud L; Patel N; Harrison SJ; Einsele H
N Engl J Med; 2023 Jul; 389(4):335-347. PubMed ID: 37272512
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness analysis of CAR-T cell therapy for patients with relapsed/refractory multiple myeloma in China.
Wu W; Ding S; Mingming Z; Yuping Z; Sun X; Zhao Z; Yang Y; Hu Y; Dong H
J Med Econ; 2023; 26(1):701-709. PubMed ID: 37145966
[TBL] [Abstract][Full Text] [Related]
19. Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1).
Mi JQ; Zhao W; Jing H; Fu W; Hu J; Chen L; Zhang Y; Yao D; Chen D; Schecter JM; Yang F; Tian X; Sun H; Zhuang SH; Ren J; Fan X; Jin J; Niu T; Chen SJ
J Clin Oncol; 2023 Feb; 41(6):1275-1284. PubMed ID: 36269898
[TBL] [Abstract][Full Text] [Related]
20. Component Costs of CAR-T Therapy in Addition to Treatment Acquisition Costs in Patients with Multiple Myeloma.
Jagannath S; Joseph N; Crivera C; Kharat A; Jackson CC; Valluri S; Cost P; Phelps H; Slowik R; Klein T; Smolen L; Yu X; Cohen AD
Oncol Ther; 2023 Jun; 11(2):263-275. PubMed ID: 37014590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]